ERK/MAPK pathway is required for changes of cyclin D1 and B1 during phorbol 12-myristate 13-acetate-induced differentiation of K562 cells

IUBMB Life. 1999 Dec;48(6):585-91. doi: 10.1080/713803574.

Abstract

Phorbol 12-myristate 13-acetate (PMA)-induced differentiation of human erythroleukemic K562 cells is characterized by growth arrest, morphological change, and expression of megakaryocyte-specific proteins. We examined the possible involvement of cell cycle regulators with PMA-induced growth arrest and megakaryocytic differentiation of K562 cells. The concentrations of cyclin D1 and p21Waf1/Cip1 were dramatically increased, whereas those of cyclin B1 and cdc2 were decreased, by PMA treatment. The concentrations of most cyclin-dependent kinases (Cdk2, Cdk4, and Cdk6), however, were unchanged by PMA treatment. PD98059, a specific inhibitor of MEK1, partially prevented the increase in cyclin D1 caused by PMA and fully reversed the down-regulation of cyclin B1 protein seen in response to PMA treatment. Thus, it is demonstrated here that the PMA-mediated changes of cyclin D1 and B1 are the result of a persistent increase in extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • Cell Differentiation / drug effects
  • Cyclin B / metabolism*
  • Cyclin B1
  • Cyclin D1 / metabolism*
  • Humans
  • K562 Cells / cytology*
  • K562 Cells / drug effects*
  • K562 Cells / enzymology
  • K562 Cells / metabolism
  • MAP Kinase Signaling System / drug effects*
  • Megakaryocytes / cytology
  • Megakaryocytes / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • Mitogen-Activated Protein Kinases / physiology*
  • Tetradecanoylphorbol Acetate / antagonists & inhibitors
  • Tetradecanoylphorbol Acetate / pharmacology*

Substances

  • CCNB1 protein, human
  • Cyclin B
  • Cyclin B1
  • Cyclin D1
  • Mitogen-Activated Protein Kinases
  • Tetradecanoylphorbol Acetate